Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) have earned an average broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and one has given a strong buy rating to the company.
Brokers have set a 12 month consensus price target of $174.50 for the company and are predicting that the company will post $1.27 EPS for the current quarter, according to Zacks. Zacks has also given Bio-Rad Laboratories an industry rank of 45 out of 265 based on the ratings given to related companies.
Shares of Bio-Rad Laboratories (NYSE:BIO) opened at 138.66 on Monday. Bio-Rad Laboratories has a 52 week low of $112.51 and a 52 week high of $152.38. The company has a 50-day moving average of $138.18 and a 200 day moving average of $141.97. The firm has a market capitalization of $4.06 billion and a P/E ratio of 39.56.
Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Tuesday, November 3rd. The company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.54 by $0.05. The business had revenue of $469.96 million for the quarter, compared to the consensus estimate of $495.55 million. The company’s revenue was down 11.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.39 earnings per share. Equities research analysts anticipate that Bio-Rad Laboratories will post $3.57 earnings per share for the current year.
Several equities research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, November 8th. Leerink Swann boosted their target price on shares of Bio-Rad Laboratories from $143.00 to $149.00 in a research report on Wednesday, November 4th.
Bio-Rad Laboratories, Inc. (NYSE:BIO) manufactures and supplies products and systems used for the life science research, healthcare, analytical chemistry and other markets. The Company offers products to separate complex chemical and biological materials, and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. The Company’s Life Science segment develops, manufactures and markets a range of over 5,000 reagents, apparatus and laboratory instruments. The Company’s Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and quality controls that serve clinical laboratories in the global diagnostics market. Bio-Rad’s product brands include Droplet Digital and BioPlex. As of December 31, 2014, the Company had direct distribution channels in over 35 countries outside the United States through subsidiaries.
For more information about research offerings from Zacks Investment Research, visit Zacks.com